Serum levels of antimüllerian hormone in early maturing girls before, during, and after suppression with GnRH agonist.
OBJECTIVE
To evaluate whether serum antimüllerian hormone (AMH) levels are affected in early maturing girls, and whether pituitary suppression by long-acting GnRH agonist (GnRH-a) affects AMH.


METHODS
Secondary analyses of a prospective clinical study.


METHODS
Tertiary pediatric center.


METHODS
Fifteen girls followed during GnRH-a treatment. Evaluations before, 3 and 12 months after initiation, as well as 6 months after discontinuation of treatment. To evaluate whether AMH levels were affected in early maturing girls, baseline levels were compared with levels in healthy girls (matched for age, n = 129; matched for pubertal Tanner stage, n = 119).


METHODS
Patients were treated with SC injections of leuprolide acetate (LA; Procren 3.75 mg every 28th day).


METHODS
Basal serum levels of AMH, E(2), inhibin B, FSH, and LH, as well as GnRH-stimulated levels of FSH and LH.


RESULTS
At baseline, the median (range) of AMH levels in the patients was 20.3 pmol/L (2.0-30.0 pmol/L). After 3 months of GnRH-a treatment, AMH declined to 10.4 pmol/L (range, <2.0-27.0 pmol/L). The AMH suppression was maintained after 12 months of treatment (14.4 pmol/L [range, <2.0-29.6 pmol/L]). Six months after discontinuation of GnRH-a treatment, AMH levels were similar to pretreatment levels (18.8 pmol/L (range, 5.8-46.9 pmol/L)). Before treatment, AMH levels in early maturing girls did not differ significantly from AMH levels in healthy age-matched girls (median, 20 vs. 23 pmol/L) or Tanner-matched girls (median, 20 vs. 19 pmol/L).


CONCLUSIONS
The partial suppression of AMH by GnRH-a treatment is consistent with previous studies suggesting partial gonadotropin-dependence of AMH.
Department of Growth and Reproduction, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark. casperhagen@gmail.com
Casper P
CP
Hagen
Kaspar
K
Sørensen
Richard A
RA
Anderson
Anders
A
Juul
D054304:Anti-Mullerian Hormone / Q000097:blood*; D015415:Biomarkers / Q000097:blood; D002648:Child; D002657:Child Development / Q000187:drug effects; D003718:Denmark; D004334:Drug Administration Schedule; D004958:Estradiol / Q000097:blood; D005260:Female; D005300:Fertility Agents, Female / Q000008:administration & dosage / Q000627:therapeutic use*; D043373:Follicle Stimulating Hormone, Human / Q000097:blood; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists* / Q000378:metabolism; D006801:Humans; D007265:Inhibins / Q000097:blood; D007279:Injections, Subcutaneous; D016729:Leuprolide / Q000008:administration & dosage / Q000627:therapeutic use*; D007986:Luteinizing Hormone / Q000097:blood; D011446:Prospective Studies; D011627:Puberty / Q000097:blood / Q000187:drug effects*; D011629:Puberty, Precocious / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D013997:Time Factors; D016896:Treatment Outcome
D015415:Biomarkers; D005300:Fertility Agents, Female; D043373:Follicle Stimulating Hormone, Human; C422364:inhibin B; D007987:Gonadotropin-Releasing Hormone; D004958:Estradiol; D007265:Inhibins; D054304:Anti-Mullerian Hormone; D007986:Luteinizing Hormone; D016729:Leuprolide